SCHEMBL22129304

SCHEMBL22129304

OCc1cnc(Cl)cc1NCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 1/20 0.49
ASPH Q12797 1/20 0.45
RIOX2 Q8IUF8 1/20 0.45
KDM8 Q8N371 1/20 0.45
ATM Q13315 1/20 0.45
PKM P14618 1/20 0.44
IDO1 P14902 1/20 0.42
VNN1 O95497 1/20 0.41
BACE1 P56817 1/20 0.41
HDAC8 Q9BY41 2/20 0.41
BRD4 O60885 1/20 0.41
KAT2B Q92831 1/20 0.41
BRD9 Q9H8M2 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
KDM6B O15054 1/20 0.40
KDM4A O75164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29743231 1.00 KDM4E (0.49) KDM4EL3MBTL1GAAMAPTASPH
SCHEMBL21722982 0.82 LMNA (0.51) KDM4EASPHRIOX2KDM8PKM
SCHEMBL30581495 0.82 LMNA (0.51) KDM4EASPHRIOX2KDM8PKM
SCHEMBL4421499 0.79 ALDH1A1 (0.39) KDM4EL3MBTL1GAAMAPTATM
SCHEMBL15749318 0.79 KDM4E (0.51) KDM4EL3MBTL1GAAMAPTASPH
SCHEMBL16491996 0.79 KDM4E (0.51) KDM4EL3MBTL1GAAMAPTASPH
SCHEMBL4409419 0.78 KDM4E (0.60) KDM4EL3MBTL1GAAMAPTASPH
SCHEMBL2480282 0.77 JAK3 (0.67) KDM4EASPHRIOX2KDM8ATM
SCHEMBL9689025 0.77 PKM (0.50) MAPTPKMIDO1HDAC8HDAC1
SCHEMBL5888558 0.77 PDE5A (0.56) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111989332-B Macrocyclic compounds as CDK inhibitors, their preparation and their use in medicine 凯复(苏州)生物医药有限公司 2022-07-26 CN disclosed
US-20220017520-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2022-01-20 US disclosed
US-20220017520-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2022-01-20 US disclosed
EP-3865488-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2021-08-18 EP disclosed
EP-3865488-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2021-08-18 EP disclosed
CN-111989332-A Macrocyclic compounds as CDK inhibitors, method for the production thereof and their use in medicine 凯复(苏州)生物医药有限公司 2020-11-24 CN disclosed
WO-2020125513-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 凯复制药有限公司 2020-06-25 WO disclosed
WO-2020125513-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 凯复制药有限公司 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017520-A1 MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE CDK4, CDK7, CDKL1 KDM4E 343/4885L3MBTL1 2843/4885GAA 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.